SecBot SecBot

VTGN drug pipeline

$0.1800
0.0% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bearish · 1 neutral
Phase 3 trials
2
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhasePhase 3 (completed — two of three Phase 3 trials failed)
Time to marketUnknown — at least 3-5+ years if a new Phase 3 trial is required, with no guarantee of FDA acceptance of the proposed path

fasedienol Updated Jul 3

What to watch

Fasedienol has now failed two consecutive Phase 3 trials (PALISADE-3 Dec 2025, PALISADE-4 June 2026). The stock traded at ~$2.04 before the PALISADE-4 miss and collapsed to ~$0.25, a ~$10M market cap. The company plans an FDA meeting for a potential new trial path, but the path to approval looks extremely long and uncertain. Watch for dilution risk as the company may need financing to fund any future trial.

Bull case
  • Novel first-in-class mechanism (pherine nasal spray) is differentiated from all approved anxiety medications, no systemic side effects, rapid onset within minutes, and no abuse potential like benzodiazepines.
  • PALISADE-2 Phase 3 trial did succeed (p=0.015), proving the drug can work. A post-hoc analysis of PALISADE-4 showed nominal significance (p=0.036) in a subgroup with very severe SAD, providing a hypothesis for a more targeted future trial.
  • FDA granted Fast Track designation, and the company has received positive FDA feedback on using the LSAS scale as a primary endpoint, the proposed new multi-dose trial design could potentially salvage the program.
Bear case
  • Two consecutive Phase 3 failures (PALISADE-3 and PALISADE-4) make it very unlikely the FDA will accept a path forward without another large, costly, and time-consuming trial.
  • PALISADE-4 primary endpoint was a decisive miss (p=0.427, far from statistical significance), and all secondary endpoints also failed. The post-hoc subgroup signal is exploratory, not confirmatory, and regulators rarely accept such analyses.
  • With a ~$10M market cap, the stock has limited room to fall but also limited ability to raise capital. A new Phase 3 trial would require significant financing, causing severe dilution at current share prices.
● neutral
Impact
PhasePreclinical / Early-stage (no clinical trials identified)
Time to marketUnknown — likely years away, if ever developed. The company's lead asset fasedienol just failed a Phase 3 trial, and with only ~$31.7M in cash (as of June 30, 2026) burning ~$13.7M/quarter, Vistagen may not have the resources to advance itruvone into the clinic without significant financing.

itruvone Updated Sep 13

What to watch

Itruvone is not a tradeable catalyst, it is a preclinical pipeline placeholder at a cash-strapped micro-cap whose lead asset just failed Phase 3. VTGN stock will move on the outcome of the FDA meeting for fasedienol and on financing events, not on itruvone. Avoid trading based on itruvone alone.

Bull case
  • Itruvone represents a potential pipeline option value at essentially zero cost, if Vistagen can secure financing or a partnership, it could eventually be developed into a clinical-stage asset.
  • The company has attracted institutional accumulation from Renaissance Technologies, Morgan Stanley, JPMorgan, and Citigroup in recent quarters, suggesting some sophisticated investors see value in the broader pipeline.
Bear case
  • Itruvone is a preclinical asset with no disclosed mechanism, indication, or clinical data, essentially a 'pipeline filler' with no tangible value for investors.
  • Vistagen has only ~$31.7M in cash and is burning ~$13.7M/quarter, giving less than 12 months of runway. The company will likely need dilutive financing just to survive, making it unlikely itruvone will ever reach the clinic.
  • The lead drug fasedienol failed its Phase 3 PALISADE-4 trial (p=0.427), severely damaging investor confidence in the company's pipeline and scientific platform.

Other drugs in filings and trials

no drug report yet
  • Fasedienol Nasal Spray 2 trials
  • Fasedienol Nasal Spray - Fasedienol Nasal Spray 1 trial

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Fasedienol Nasal Spray - Fasedienol Nasal SprayA Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety DisorderPhase 2Completed61Jun 12, 2026
Fasedienol Nasal SprayFasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)Phase 3Completed238Apr 21, 2026
Fasedienol Nasal SprayFasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)Phase 3Completed238Oct 31, 2025